Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

Greenberg Traurig Bolsters Health Care & FDA Practice with Gail Javitt in Washington, D.C.

RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results

Physicians Bring Medicare Same-Day Care Concerns to Congress